United States:
Unsuccessfully Using The Wayback Machine To Establish Status As A Printed Publication, PTAB Litigation Blog
To print this article, all you need is to be registered or login on Mondaq.com.
On March 6, 2017, the PTAB issued a pair of final written
decisions upholding the patentability of U.S. Patent Nos. 7,932,268
(IPR2015-01836) and 8,618,135 (IPR2015-01835), in challenges filed
by the Coalition for Affordable Drugs VIII, LLC (CFAD). The patents
are owned by the University of Pennsylvania, and are licensed to
Aegerion Pharmaceuticals, Inc. (a subsidiary of Novelion
Therapeutics Inc.). Both patents relate to methods for using
lomitapide, an MTP inhibitor, in the treatment of hyperlipidemia
and/or hypercholesterolemia. Aegerion markets a lomitapide product
under the name "JUXTAPID®."
Read the full article at
ptablitigationblog.com.
The content of this article is intended to provide a general
guide to the subject matter. Specialist advice should be sought
about your specific circumstances.
POPULAR ARTICLES ON: Intellectual Property from United States
USPTO Embraces AI Tools In New Guidance
Crowell & Moring LLP
On April 11, 2024, the USPTO published its "Guidance on Use of Artificial Intelligence-Based Tools in Practice Before the United States" in the Federal Register (the "Guidance"). As the title suggests...
Breaking Down The EPO's Revised Practice Guidelines
Finnegan, Henderson, Farabow, Garrett & Dunner, LLP
The guidelines for examination in the European Patent Office instruct on the practice and procedure related to the examination of European patent applications...
USPTO Issues Guidance On Use Of AI-Based Tools
Greenberg Traurig, LLP
On April 11, 2024, the U.S. Patent and Trademark Office (USPTO) issued Guidance on Use of Artificial-Intelligence-Based Tools (Guidance), which applies existing rules and policies...